![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Exact Sciences’ Colorectal Cancer Test Gets Expanded Indication
Exact Sciences’ Colorectal Cancer Test Gets Expanded Indication
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
The FDA approved Exact Sciences’ noninvasive colorectal cancer screening test, Cologuard, for eligible patients aged 45 years and older.
The at-home diagnostic test’s new indication expands the screening age by five years during a time when incidences of colorectal cancer are rising in patients under 50.
Cologuard is a stool DNA-based colorectal cancer screening test for average-risk individuals. The test uses a biomarker panel, which analyzes a stool sample for 10 DNA markers.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct